anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Infantile spasms are recognized as epileptic encephalopathy which include the hypsarrhythmia or variants electroencephalographic (EEG) features and psychomotor regression. Various underlying conditions are associated with the infantile spasm included cerebral malformation, hypoxic ischemic encephalopathy, genetic disorders (Down syndrome), tuberous sclerosis complex (TSC), etc. Although vigabatrin has the evidence to use as the first line treatment for infantile spasm related with TSC. Adrenocorticotrophic hormone (ACTH), or high dose prednisolone, or vigabatrin are the first line treatment of IS in non-TSC.

The effectiveness of ACTH versus high dose prednisolone question have not yet definitely answered. Furthermore, ACTH expense and availability are the barriers in developing countries including Thailand. Vigabatrin, therefore, is the first option of therapy recommended by Epilepsy Society of Thailand due to ACTH unavailability. Recently, combined steroid treatments (either ACTH or high dose prednisolone) with vigabatrin are superior in cessation of spasms compared to steroid treatment alone. Questions about the clinical cessation of IS and electrographic remission by combination treatment with vigabatrin and high dose prednisolone compare to vigabatrin alone have not fully elucidated. Thus, this study is aimed to compare the efficacy of vigabatrin with high dose prednisolone combination therapy and vigabatrin alone.
Outpatient physical therapy is an integral aspect in combating the impairment and dysfunction associated with musculoskeletal injuries. Healthcare and insurance restrictions are leading to reduced clinic visits, encouraging efficient and effective treatments and focusing a greater demand on education, proactive wellness and home exercise maintenance. Home exercise prescription has long been a fundamental aspect to a physical therapy routine or regimen. It is well established that exercise protocols can positively impact pain, fitness levels, physical function and measures of life quality (Forkan, Pumper, Smyth, Wirkkala, A Ciol, \& Shumway-Cook, 2006). It is also recognized that treatment outcomes may be negatively impacted by non-adherence to the prescribed exercise recommendation in rehabilitation (Holden, Haywood, Portia, Gee, \& Mclean, 2014). Research historically suggests that levels of non-adherence to exercise prescription range from 50-70% (Bassett, 2003; Sluijs, Kok, \& van der Zee, 1993), and likely increase as time passes. Investigating non-adherence demonstrates a myriad of influencing factors. These factors can be characterized as motivators and barriers. With the explosion of mobile communications access and increasing number of active device users, healthcare is embarking on the concept of mobile health management. Mobile health interventions have been found to have a positive impact in the arenas of medication compliance, weight loss, chronic disease management and postoperative complication (Lee, 2016; Ronghua, Li, (2015).The implementation of a mobile health application in physical therapy outpatient management has not been well established. It is time to investigate the impact of using a mobile health application on a prescribed physical therapy treatment regimen for the enhancement of HEP adherence and functional outcome assessment.
The invention discloses a traditional Chinese medicine composition for treating encephalatrophy. The encephalatrophy belongs to the category of aphronesia, amnesia, fremitus and the like in traditional Chinese medicine. The brain marrow emptiness is the basic pathological change of senile dementia, and the deficiency of kidney-qi and kidney-essence is the basic pathogenesis of the senile dementia. The traditional Chinese medicine composition is decoction prepared by decocting traditional Chinese medicines with the effects of tonifying the kidney, replenishing essence and benefiting marrows, including unpleasant swallowwort herb, human placentae, flatstem milkvetch seed, asiatic bilberry leaf, Fluggea suffruticosa(Pall.)Baill., woody-rhizomed fimbristylis herb, silene conoidea, simon plum root or leaf, laxflower pottsia root, asiatic cudweed, Indian melothria root and gigantism rhodobryum herb, with water. Clinical experiments prove that the total effective rate of the traditional Chinese medicine composition reaches 96.7%, and the traditional Chinese medicine composition has a relatively good treatment effect.
PCT No. PCT/ES96/00116 Sec. 371 Date Feb. 27, 1997 Sec. 102(e) Date Feb. 27, 1997 PCT Filed May 24, 1996 PCT Pub. No. WO96/37232 PCT Pub. Date Nov. 28, 1996Stabilization of colloidal systems through the formation of lipid-polyssacharide complexes. Development of a procedure for the preparation of colloidal systems involving a combination of two ingredients: a water soluble and positively charged polyssacharide and a negatively charged phospholipid. Colloidal systems (submicron emulsions and polymeric nanoparticles and nanocapsules) are stabilized through the formation, at the interface, of an ionic complex: aminopolyssachride-phospholipid. These colloidal systems are characterized by their positive charge and their improved stability. Furthermore, they can be freeze-dried, stored in a dry state and hydrated when required. They can be interesting systems for the administration of drugs by the oral, transdermal, ocular, nasal and vaginal routes of administration. In addition, they can be of interest for cosmetic use.
T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sezary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors studied the regulatory T phenotype of Sezary cells and showed the expression of CCR8 (CD198) by Sezary cells and other T-cell lymphoma cell lines. CCR8 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CCR8-expressing cancer cells would eliminate tumor cells and also activate the anti-tumor immunity in T-cell lymphomas.
Tbi patients with acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
PROBLEM TO BE SOLVED: To obtain an agent for oral administration having masked bitter taste by mixing a quinolone derivative having antibacterial activity with a higher fatty acid and heating the mixture. SOLUTION: This agent is produced by mixing a quinolone derivative with at least one higher fatty acid, optionally adding an additive, heating the mixture at 30-140 deg.C, preferably at 50-85 deg.C and crushing to powder or granule after cooling. The weight ratio of the quinolone derivative to the fatty acid is 1:(0.3-4). The quinolone derivative is e.g. levofloxacin or ofloxacin and the fatty acid is a >=10C acid such as stearic acid or palmitic acid. A drug preparation necessary to eliminate the taste of an active compound such as soluble tablet, chewable agent and sachet is produced and the active antibacterial quinolone derivative is quickly released by this process. The agent is useful for the treatment of bacteriosis.
A charting system is provided for use in a healthcare facility having a network. The charting system includes a microphone to receive voice inputs from a caregiver. A vital sign monitor obtains a vital sign from a patient and displays it. The system includes a communication device having a voice-to-text module that includes a processor coupled to the microphone. The processor operates a voice-to-text algorithm that converts the vital sign into text in response to the caregiver dictating the vital sign into the microphone. The processor initiates transmission of the vital sign to an EMR computer via the network after conversion of the at least one vital sign to text.
A single 1.5-milligram (mg) dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2).
BACKGROUND: There are no reports on home-based physiotherapy after femoral shaft re-fractures in children. Here we report a case involving a child who sustained a femoral shaft re-fracture and returned to kindergarten after 2 months of home-based physiotherapy.
CASE: A 4-year-old girl presented at an emergency hospital with severe pain in the right lower limb and the inability to walk after falling at home, 15 days after discharge following treatment of a right femoral shaft fracture at the same hospital. Radiography was performed and she was diagnosed with a right femoral shaft re-fracture. Following her second discharge, she underwent home-based physiotherapy 3 days/week (40 min/day). She experienced muscle weakness in both lower limbs and a decline in the ability to stand on one leg. Consequently, she required walking assistance because of anxiety and fear of falling. Her walking ability, activities of daily living, pain, bone deformity, leg length discrepancy, anteversion of the femur (Craig's test), range of motion of both lower limbs, the circumference of the thigh and lower leg, muscle strength of both lower limbs, and standing balance (standing on one leg) were assessed.
OUTCOMES: No severe adverse events were associated with home-based physiotherapy. The patient could walk independently without pain or fear of falling and returned to kindergarten 118 days after the re-fracture.
CONCLUSIONS: For paediatric patients with femoral shaft fractures, home-based physiotherapy is recommended to improve motor functions and activities of daily living and to facilitate return to kindergarten or school.
CHARMS Intervention Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
PURPOSE: A Viscum album extract with anti-aging activity is provided to ensure life extension and to improve human health by being applied to functional foods or pharmaceutical compositions. CONSTITUTION: A Viscum album extract has an anti-aging activity. The Viscum album extract is obtained by cold water extraction or hot water extraction. The cold water extraction is performed by adding 1L of water to 200g of Viscum album and stirring for 2-4 hours. The hot water extraction is performed by adding 1L of water to 200 of Viscum album cold water extract and heating at 100°C for 30 minutes. A functional food composition with anti-aging activity contains Viscum album extract as an active ingredient. A pharmaceutical composition for anti-aging activity contains Viscum album extract as an active ingredient.
Diagnosis and management of type 1 diabetes (T1D) have remained largely unchanged for the last several years. The management of the disease remains primarily focused on its phenotypical presentation and less on endotypes, namely the specific biological mechanisms behind the development of the disease. Furthermore, the treatment of T1D is essentially universal and indiscriminate-with patients administering insulin at varying dosages and frequencies to maintain adequate glycaemic control. However, it is now well understood that T1D is a heterogeneous disease with many different biological mechanisms (i.e. endotypes) behind its complex pathophysiology. A range of factors, including age of onset, immune system regulation, rate of β-cell destruction, autoantibodies, body weight, genetics and the exposome are recognised to play a role in the development of the condition. Patients can be classified into distinct diabetic subtypes based on these factors, which can be used to categorise patients into specific endotypes. The classification of patients into endotypes allows for a greater understanding of the natural progression of the disease, giving rise to more accurate and patient-centred therapies and follow-up monitoring, specifically for other autoimmune diseases. This review proposes 6 unique endotypes of T1D based on the current literature. The recognition of these endotypes could then be used to direct therapeutic modalities based on patients' individual pathophysiology.
BACKGROUND: Among the anthropometric measurements, calf circumference has been widely used as a simple and practical method to diagnose low muscle mass and sarcopenia. However, the association between this measurement and clinical outcomes in people receiving home enteral nutrition is still unknown. Therefore, this study aimed to investigate the association of calf circumference with mortality, discharge from home enteral nutrition, continuity in home enteral nutrition, and new hospitalizations in adult and older adult people.
METHODS: This retrospective cohort study used secondary data, including people aged ≥18 years receiving home enteral nutrition. The association between calf circumference and the outcomes of mortality, discharge from home enteral nutrition, and continuity in home enteral nutrition was analyzed using multinomial logistic regression. The association between calf circumference and the occurrence of new hospitalizations was investigated using binary logistic regression.
RESULTS: Among the 899 people included in the study, 470 were men (52.3%), the median age was 72 years (interquartile range, 56.5-82), and 850 had inadequate calf circumference (94.5%). As calf circumference increased, the odds of mortality decreased and the probability of discharge from home enteral nutrition and continuity in home enteral nutrition increased. Furthermore, in people with oncologic diagnoses, the odds of new hospitalizations were reduced by 71.9% for each additional centimeter in calf circumference.
CONCLUSION: These findings underline the importance of using calf circumference as part of the nutrition assessment because it is a simple, easy, and cost-effective method that can also be used as a tool to predict clinical outcomes.
The exercises to be applied to the control group for 6 weeks will be given to the intervention group in the same order and at weekly intervals. Additionally, Robacado exercises (jaw exercises) will be given to the individuals in this group.
The COVID-19 pandemic has resulted in a global health crisis that has severely impacted patients with type 2 diabetes (T2D). T2D patients have a higher risk of experiencing severe COVID-19 symptoms, hospitalization, and mortality compared to patients without diabetes. The dysregulated immune response in T2D patients can exacerbate the severity of COVID-19 symptoms. Insulin therapy, a common treatment for T2D patients, has been linked to increased mortality in COVID-19 patients with T2D. However, metformin, an anti-diabetic medication, has been shown to have anti-inflammatory properties that may mitigate the cytokine storm observed in severe COVID-19 cases. In this study, we investigated how the PRKAA1, SLC2A1, and MTOR genes contribute to inflammation markers in COVID-19 patients with T2D, who were receiving either insulin or metformin therapy. Our findings revealed that metformin treatment was associated with reduced expression of genes involved in Th1/Th17 cell differentiation. These results suggest that metformin could be a potential treatment option for T2D patients with COVID-19 due to its anti-inflammatory properties, which may improve patient outcomes.
Participants will receive PLX9486 250 milligrams (mg) orally once daily (QD) in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
Chronic wasting disease (CWD) has become a major concern among those involved in managing wild and captive cervid populations. CWD is a fatal, highly transmissible spongiform encephalopathy caused by an abnormally folded protein, called a prion. Prions are present in a number of tissues, including feces and urine in CWD infected animals, suggesting multiple modes of transmission, including animal-to-animal, environmental, and by fomite. CWD management is complicated by the lack of practical, non-invasive, live-animal screening tests. Recently, there has been a focus on how the volatile odors of feces and urine can be used to discriminate between infected and noninfected animals in several different species. Such a tool may prove useful in identifying potentially infected live animals, carcasses, urine, feces, and contaminated environments. Toward this goal, dogs were trained to detect and discriminate CWD infected individuals from non-infected deer in a laboratory setting. Dogs were tested with novel panels of fecal samples demonstrating the dogs' ability to generalize a learned odor profile to novel odor samples based on infection status. Additionally, dogs were transitioned from alerting to fecal samples to an odor profile that consisted of CWD infection status with a different odor background using different sections of gastrointestinal tracts. These results indicated that canine biodetectors can discriminate the specific odors emitted from the feces of non-infected versus CWD infected white-tailed deer as well as generalizing the learned response to other tissues collected from infected individuals. These findings suggest that the health status of wild and farmed cervids can be evaluated non-invasively for CWD infection via monitoring of volatile metabolites thereby providing an effective tool for rapid CWD surveillance.
A medical adhesive consists of foundation (A) based on an ABA-block copolymer, a sticky-making component, an oil component, a hydrophilic polymer and water, into which has been worked (B) a disulphide bond contg. medicinal active ingredient. USE/ADVANTAGE - The medical adhesive does not contain any components which would deactivate a medicament contg. disulphide bonds. The disulphide bond contg. component is stable in the adhesive, which has a long-lasting high degree of adhesiveness, ensures percutaneous absorption, has long-lasting analgesic/antiinflammaotry action, is capable of taking up water and does not lose its adhesiveness on transcription. There are not significant side effects and the cooling effect of water is utiliseent
The invention relates to hydroxyl phosphate amino acid ester derivatives of Brefeldin A, a preparation method thereof, and an application thereof. The invention relates to a fungal metabolite. The derivatives comprises (+)-Brefeldin A-4,7-dihydroxyl phosphate amino acid ester, (+)-Brefeldin A-4-hydroxyl phosphate amino acid ester, and (+)-Brefeldin A-7-hydroxyl phosphate amino acid ester. According to the invention, Brefeldin A hydroxyl phosphate amino acid ester derivatives with high bioactivity, good dissolubility, and good bioavailability are synthesized. The derivatives are simple to prepare, and the cost is low. The derivatives are advantaged in novel structure, relatively stable structure, and substantial inhibitive activities against tumor cell proliferation. Compared with the original medicine (+)-Brefeldin A, the derivatives are advantaged in good dissolubility and long half-life period. The Brefeldin A hydroxyl phosphate amino acid ester derivatives can be applied in the preparations of anticancer medicines.
LANTUS (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as a subcutaneous injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent [See Clinical Pharmacology (12)]. LANTUS is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, insulin glargine is 21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063. Insulin glargine has the following structural formula:

LANTUS consists of insulin glargine dissolved in a clear aqueous fluid. Each milliliter of LANTUS (insulin glargine injection) contains 100 Units (3.6378 mg) insulin glargine.

The 10 mL vial presentation contains the following inactive ingredients per mL: 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, 20 mcg polysorbate 20, and water for injection. 

The 3 mL cartridge presentation contains the following inactive ingredients per mL: 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, and water for injection. 

The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. LANTUS has a pH of approximately 4.
The invention mainly relates to burn and scald liquid enabling a scar not to be left. The burn and scald liquid enabling the scar not to be left comprises, by weight, 20-40 parts of egg white, 0.1-4 parts of calomel, 0.2-1.2 parts of rifampicin, 40-60 parts of ethyl alcohol and 200-300 parts of distilled water, wherein the mass concentration of the ethyl alcohol is larger than or equal to 50%. The burn and scald liquid enabling the scar not to be left is suitable for various burns and scalds, such as a lime burn, a powder burn, an electric burn and a boiling water burn. After a person is burned, the burn and scald liquid is instantly prepared and applied. The burn and scald liquid is capable of producing the instant analgesia and detumescence effects and diminishing inflammation of the surface, remarkable in granulation promoting and inflammation diminishing effect, and capable of enabling the recovery speed to be high and enabling the scar not to be left after recovery. The burn and scald liquid is suitable for being used instantly after the person is burned or scalded, if other medicine is applied firstly, the burn and scald liquid can replace other medicine, and the burn and scald liquid produces an instant effect after being applied, and can reduce the possibility of appearance of the scar.
Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
Clavispora lusitaniae has been isolated from different substrates, such as soil, water, fruit, vegetables, plants, and the gastrointestinal tract of animals and humans. However, its importance lies in being isolated from in invasive infections, particularly in pediatric patients with hematologic malignancies. It is an emerging nosocomial pathogen commonly associated with fatal prognosis in immunocompromised hosts. C. lusitaniae has attracted attention in the last decade because of resistance to amphotericin B, 5- flucytosine, and fluconazole. The adaptations of this yeast to the human host may contribute to its pathogenicity. Further study will be needed to understand C. lusitaniae's ability as a potential pathogen. This mini-review highlights the importance of the growing number of invasive disease cases caused by this yeast.